Share on StockTwits

Valeant Pharmaceuticals Intl (NYSE:VRX) is scheduled to release its Q114 earnings data on Thursday, May 8th. Valeant Pharmaceuticals Intl has set its FY14 guidance at $8.25-8.75 EPS.

Valeant Pharmaceuticals Intl (NYSE:VRX) last issued its quarterly earnings data on Thursday, February 27th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $2.06 by $0.09. The company had revenue of $2.06 billion for the quarter, compared to the consensus estimate of $986.30 million. During the same quarter in the previous year, the company posted $1.22 earnings per share. The company’s revenue for the quarter was up 109.2% on a year-over-year basis. On average, analysts expect Valeant Pharmaceuticals Intl to post $8.70 EPS for the current fiscal year and $10.64 EPS for the next fiscal year.

Shares of Valeant Pharmaceuticals Intl (NYSE:VRX) traded down 1.04% on Wednesday, hitting $131.96. The stock had a trading volume of 1,735,791 shares. Valeant Pharmaceuticals Intl has a 52 week low of $72.25 and a 52 week high of $153.10. The stock’s 50-day moving average is $130.3 and its 200-day moving average is $125.2. The company’s market cap is $44.189 billion.

VRX has been the subject of a number of recent research reports. Analysts at Jefferies Group reiterated a “buy” rating on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, April 30th. They now have a $153.00 price target on the stock. On the ratings front, analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a research note on Wednesday, April 23rd. They now have a $180.00 price target on the stock. Finally, analysts at TD Securities upgraded shares of Valeant Pharmaceuticals Intl from a “hold” rating to a “buy” rating in a research note on Wednesday, April 23rd. They now have a $160.00 price target on the stock, up previously from $145.00. One investment analyst has rated the stock with a hold rating, fifteen have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and an average target price of $146.41.

Valeant Pharmaceuticals International, Inc, formerly Biovail Corporation, is a multinational, specialty pharmaceutical company that develops, manufactures and markets a range of pharmaceutical products.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.